Prospects for new and emerging therapeutics in severe asthma: the role of biologics

Ozdemir S. K., BAVBEK S.

EXPERT REVIEW OF RESPIRATORY MEDICINE, cilt.11, sa.6, ss.505-512, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 6
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/17476348.2017.1326821
  • Dergi Adı: EXPERT REVIEW OF RESPIRATORY MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.505-512
  • Anahtar Kelimeler: Severe asthma, uncontrolled asthma, biologic agents, biologics, new treatments, DOUBLE-BLIND, EOSINOPHILIC ASTHMA, ALLERGIC-ASTHMA, ANTI-IGE, INHALED CORTICOSTEROIDS, MONOCLONAL-ANTIBODY, UNCONTROLLED ASTHMA, PERSISTENT ASTHMA, OMALIZUMAB, EFFICACY
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction: Asthma is a common and heterogeneous disease. While current conventional therapies are effective in the majority of the patients, a significant subgroup remain uncontrolled despite these treatments. Different biological agents are currently approved or undergoing development for treatment of asthma, including anti-IgE, anti-interleukin (IL)-5, anti-IL-13, anti-IL-4 and anti-thymic stromal lymphopoietin agents. This review will focus on the currently available evidence regarding the new and emerging biological agents in severe asthma.Areas covered: A non-systematic review of the available English-language literature regarding severe asthma and biological agents was performed. We summarized and discussed the current evidence about the use of new and emerging biological agents in severe asthma.Expert commentary: Because of the heterogeneity of response to therapy in refractory asthma it is of utmost importance to correctly estimate patient outcomes before starting biological therapy to make patient selection more effective. Currently, the decision of which biologic to initiate in patients with uncontrolled severe asthma should be made based on the atopic status, blood eosinophil and total IgE levels, exacerbation history, safety profile, cost, frequency and route of administration.